Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial

被引：0
|
作者：
Hida, T. [1 ]
Katayama, R. [2 ]
Nishio, M. [3 ]
Yoshida, T. [4 ]
Kumagai, T. [5 ]
Toyozawa, R. [6 ]
Shimokawaji, T. [7 ]
Goto, K. [8 ]
Nakagawa, K. [9 ]
Seto, T. [10 ]
Yamamoto, N. [11 ]
Asato, T. [12 ]
Hiraoka, K. [13 ]
Zhang, P. [14 ]
Ohe, Y. [15 ]
机构：
[1] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi, Japan
[2] Japanese Fdn Canc Res, Div Expt Chemotherapy, Ctr Canc Chemotherapy, Tokyo, Japan
[3] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Canc Inst Hosp, Tokyo, Japan
[4] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[9] Kindai Univ, Fac Med, Dept Med Oncol, Higashiosaka, Osaka, Japan
[10] NHO Kyushu Canc Ctr, Thorac Oncol, Fukuoka, Japan
[11] Wakayama Med Univ, Wakayama, Japan
[12] Takeda Pharmaceut Co Ltd, Oncol Therapeut Area Unit Japan & Asia, Tokyo, Japan
[13] Takeda Pharmaceut Co Ltd, Japan Oncol Business Unit, Tokyo, Japan
[14] Millennium Pharmaceut Inc, Cambridge, MA USA
[15] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
brigatinib; alectinib-resistant; ALK-positive NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75.01
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 50 条
  • [41] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
    Camidge, D. Ross
    Tiseo, Marcello
    Ahn, Myung-Ju
    Reckamp, Karen
    Hansen, Karin
    Kim, Sang-We
    Huber, Rudolf
    West, Howard
    Groen, Harry
    Hochmair, Maximilian
    Leighl, Natasha
    Gettinger, Scott
    Langer, Corey
    Paz-Ares, Luis
    Smit, Egbert
    Kim, Edward
    Reichmann, William
    Clackson, Tim
    Kerstein, David
    Haluska, Frank
    Kim, Dong-Wan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1169
  • [42] Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)
    Kim, Young
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S378 - S379
  • [43] Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC
    Hochmair, M.
    Ahn, M-J
    Camidge, D. R.
    Tiseo, M.
    Reckamp, K.
    Hansen, Holmskov K.
    Kim, S-W
    Huber, R.
    West, H.
    Groen, H.
    Leighl, N.
    Gettinger, S.
    Langer, C.
    Paz-Ares Rodriguez, L.
    Smit, E.
    Kim, E.
    Reichmann, W.
    Kerstein, D.
    Kim, D-W
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 271 - 271
  • [44] Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (vol 27,pg 1828, 2022)
    Sugawara, Shunichi
    Kondo, Masashi
    Yokoyama, Toshihide
    Kumagai, Toru
    Nishio, Makoto
    Goto, Koichi
    Nakagawa, Kazuhiko
    Seto, Takashi
    Yamamoto, Nobuyuki
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Ohe, Yuichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (05) : 724 - 725
  • [45] Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial
    Camidge, R.
    Kim, H. R.
    Ahn, M-J.
    Yang, J. C-H.
    Han, J-Y.
    Hochmair, M. J.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D-W.
    Griesinger, F.
    Felip, E.
    Califano, R.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [46] Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Garcia Campelo, Maria Rosario
    Kim, Dong-Wan
    Griesinger, Frank
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Gupta, Neeraj
    Hanley, Michael J.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3592 - +
  • [47] Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
    Leonetti, A.
    Minari, R.
    Boni, L.
    Gnetti, L.
    Bordi, P.
    Verze, M.
    Ampollini, L.
    Gelsomino, F.
    Toschi, L.
    Cecere, F.
    Pilotto, S.
    Metro, G.
    Passiglia, F.
    Cortinovis, D.
    Guaitoli, G.
    Pasello, G.
    Delmonte, A.
    Mazzoni, F.
    Bria, E.
    Galetta, D.
    Genova, C.
    Rocco, D.
    Parra, H. Soto
    Bearz, A.
    Migliorino, M. R.
    Camerini, A.
    Tognetto, M.
    Tiseo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S231 - S231
  • [48] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
    Griesinger, Frank
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji Youn
    Hochmair, Maximilian
    Lee, Hyeong
    Delmonte, Angelo
    Garcia Compelo, Maria Rosario
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spire, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
  • [49] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC).
    Yoshioka, Hiroshige
    Hida, Toyoaki
    Nokihara, Hiroshi
    Morise, Masahiro
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Kumagai, Toru
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Yoshimoto, Takuya
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial
    Ahn, M. -J.
    Delmonte, A.
    Ghosh, S.
    Hochmair, M.
    Yang, T. -Y.
    Yang, J. C. -H.
    Han, J. -Y.
    Hansen, K. Holmskov
    Wu, Y.
    Wan, Y.
    Lin, H. M.
    Kretz, J.
    Hupf, B.
    Kurec, A. M.
    Churchill, E. N.
    Fram, R. J.
    Cabasag, C. J.
    Goriya, V.
    Zhao, Y.
    Gemmen, E.
    Campelo, M. R. Garcia
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S200 - S200
12345